Status:
COMPLETED
A Cross-sectional Study on the Prevalence and Extraesophageal Symptoms of Gastroesophageal Reflux Disease(GERD) in Patients With Upper GI Symptoms, Visiting the Outpatient Departments of Peripheral Hospitals in Greece
Lead Sponsor:
AstraZeneca
Conditions:
Gastroesophageal Reflux Disease
Eligibility:
All Genders
18+ years
Brief Summary
The present study has been designed to provide current data on GERD prevalence in several regional areas of Greece outside the two major urban centres (Athens and Thessaloniki), to measure the treatme...
Eligibility Criteria
Inclusion
- Provision of written informed consent
- Patients aged 18 and over
- Patients with upper-GI symptoms during the last week prior to the study visit
Exclusion
- History of oesophageal, gastric or duodenal surgery
- Patients with history of malignancy
- Treatment with acetylsalicylic acid/NSAID during the last week prior to the study visit
- Therapy with PPI for the healing of ulcer induced by treatment with acetylsalicylic acid/NSAID
- Therapy with PPI for HP eradication or for healing of HP-related peptic ulcer
Key Trial Info
Start Date :
October 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2011
Estimated Enrollment :
600 Patients enrolled
Trial Details
Trial ID
NCT01215305
Start Date
October 1 2010
End Date
March 1 2011
Last Update
April 6 2011
Active Locations (19)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Chania, Crete, Greece
2
Research Site
Rhodes, Dodekanis, Greece
3
Research Site
Ioannina, Ipiros, Greece
4
Research Site
Preveza, Ipiros, Greece